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Spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), and spinal-bulbar
muscular atrophy (SBMA) are devastating diseases characterized by the degeneration of
motor neurons. Although the molecular causes underlying these diseases differ, recent
findings have highlighted the contribution of intrinsic skeletal muscle defects in motor
neuron diseases. The use of cell culture and animal models has led to the important finding
that muscle defects occur prior to and independently of motor neuron degeneration in
motor neuron diseases. In SMA for instance, the muscle specific requirements of the SMA
disease-causing gene have been demonstrated by a series of genetic rescue experiments
in SMA models. Conditional ALS mouse models expressing a muscle specific mutant
SOD1 gene develop atrophy and muscle degeneration in the absence of motor neuron
pathology. Treating SBMA mice by over-expressing IGF-1 in a skeletal muscle-specific
manner attenuates disease severity and improves motor neuron pathology. In the present
review, we provide an in depth description of muscle intrinsic defects, and discuss how
they impact muscle function in these diseases. Furthermore, we discuss muscle-specific
therapeutic strategies used to treat animal models of SMA, ALS, and SBMA. The study of
intrinsic skeletal muscle defects is crucial for the understanding of the pathophysiology of
these diseases and will open new therapeutic options for the treatment of motor neuron
diseases.
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INTRODUCTION
Everything from physical exercise to daily chores and even breath-
ing depends on force generated by skeletal muscles. For a skeletal
muscle to produce a contraction, a signal in the form of an
action potential is required. The motor neuron is responsible for
providing this required signal. The site where the motor neu-
ron joins the muscle is called the neuromuscular junction and
together, the motor neuron and the muscle are referred to as the
motor unit.
Defects in the motor unit can seriously impact muscle con-
traction generation and lead to severely disabling diseases. Motor
neuron diseases consist of a group of conditions characterized by
motor neuron loss and atrophy of the associated musculature.
Spinal muscular atrophy (SMA), amyotrophic lateral sclerosis
(ALS), and spinal-bulbar muscular atrophy (SBMA) are examples
of suchmotor neuron diseases. Although these diseases have quite
different etiologies, SMA, ALS, or SBMA are all typified by pro-
gressive paralysis resulting in severe disability, and are commonly
fatal.
Although the importance of motor neuron pathology is well-
established in these diseases, recent work has revealed an involve-
ment of other cell types, including myocytes, in the pathogenic
process (Bricceno et al., 2012a; Hamilton and Gillingwater, 2013).
Muscle weakness and atrophy are often tightly associated with
motor neuron pathology. Importantly, however, use of both cell
culture and conditional mouse models has revealed defects in
skeletal muscle that occur in the absence of defective motor
neurons. Such studies highlight a potential contribution of skele-
tal muscle defects to the symptoms of SMA, ALS, and SBMA
patients. These findings have major implications for the devel-
opment of therapeutics for these diseases. In the current review,
we discuss the latest findings regarding intrinsic muscle defects as




SMA represents the leading genetic cause of infant death, affect-
ing 1 in 10,000 live births per year (Pearn, 1978; Prior et al., 2010).
Clinically, it is typified by progressive muscle weakness and loss
of alpha motor neurons from the spinal cord. SMA is caused by
mutations or deletions in the SMN1 gene (Lefebvre et al., 1995).
Due to a second, partially functionally copy, named SMN2, SMA
is a disease of low SMN levels, rather than no SMN (Brzustowicz
et al., 1993; Rochette et al., 2001). The clinical severity of SMA
is categorized into 4 main types, which vary in their time of
onset and expected prognosis (reviewed in Boyer et al., 2010).
Furthermore, SMN2 serves as a disease modifier since the copy
number of the SMN2 gene in SMA patients modulates disease
severity.
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The SMN protein is ubiquitously expressed and localizes to the
nucleus and cytoplasm (Liu and Dreyfuss, 1996). In the nucleus,
SMN is present in gemini of coiled bodies (gems) which are
structures associated with Cajal bodies (Liu and Dreyfuss, 1996;
Coovert et al., 1997; Lefebvre et al., 1997). Here, SMN forms a
complex with Gemin 2–8 as well as with Sm proteins to regu-
late small nuclear ribonucleoprotein (snRNP) biogenesis (Liu and
Dreyfuss, 1996; Meister et al., 2000; Pellizzoni et al., 2002; Ogawa
et al., 2007). SnRNPs are essential for pre-mRNA splicing and
a decrease in SMN produces a reduction in snRNP assembly in
SMA patients (Will and Luhrmann, 2001; Wan et al., 2005). In
additional to SMN’s established role in snRNP biogenesis, it has
also been suggested to have a role in transcription and mRNA
transport (Pellizzoni et al., 2001; Meister et al., 2002; Paushkin
et al., 2002; Rossoll et al., 2003; Kariya et al., 2008).
Since the identification of SMN as the disease-causing gene
in SMA, a number of mouse models have been generated to
gain insight into the pathogenic process. Smn knockout mice
(Smn−/−) are embryonic lethal while heterozygous (Smn+/−)
mice can be used as a model of very mild SMA (Schrank et al.,
1997). Mice do not harbor the SMN2 gene as it is unique to
humans, but by introducing low copies of the human SMN2 gene
into the Smn−/−background, researchers were able generate a
mouse model (Smn−/−;SMN2) mimicking the severe SMA phe-
notype (Monani et al., 2000). Although the Smn−/−;SMN2model
is genetically representative of human patients, these mutant mice
are very small in size and have a short life span making them diffi-
cult models to work with, especially when assessing therapeutics.
The recent creation of milder SMAmodel mice has led to the dis-
covery that cell types other than motor neurons are also affected
in SMA (Hammond et al., 2010; Michaud et al., 2010; Bowerman
et al., 2012a,b; Osborne et al., 2012; Cobb et al., 2013). These mice
will also allow for the identification of newmechanisms of disease
and will facilitate testing of therapeutic approaches.
MUSCLE INTRINSIC DEFECTS
As motor neurons and skeletal muscle are both functionally and
structurally connected, it is difficult to study skeletal muscle
defects independently from diseased motor neurons. The use of
cell culture and conditional mouse models has, however, allowed
researchers to study the role of Smn in skeletal muscle. Shafey
et al. (2005) generated a series of hypomorphic cell lines in
which Smn expression was depleted to varying levels in C2C12
myoblasts. Upon reducing Smn levels, defects such as decreased
proliferation, aberrant myoblast fusion and malformed myotubes
became apparent. These findings demonstrate that low Smn lev-
els can result in intrinsic muscle defects and suggest a role for
Smn in myoblast fusion. In vivo, the importance of Smn has been
highlighted by conditional knockout mice in which the muscle-
specific knockout of Smn was achieved using a floxed Smn allele
with Cre recombinase controlled by the human skeletal actin
(HSA) muscle-specific promoter (Cifuentes-Diaz et al., 2001).
These mice develop a phenotype reminiscent of that observed
in mouse models of muscular dystrophy. Skeletal muscle fibers
from these mice have a disorganized sarcolemma and the mice
have a reduced lifespan without displaying any overt neuropathol-
ogy (Cifuentes-Diaz et al., 2001; Nicole et al., 2003). Although
the results from conditional mouse studies have demonstrated
a need for Smn in skeletal muscle, advances in animal genetic
manipulation now allows for conditional deletion of Smn with
residual SMN2 expression. Therefore, we propose that skeletal
muscle conditional SMA model mice be revisited using genetics
reminiscent of the human disease.
Studies demonstrating muscle intrinsic defects have also been
performed using human primary myoblasts from SMA patients.
Upon differentiation of human myoblasts, myotubes from SMA
patients displayed a reduction in fusion (Arnold et al., 2004),
a result reminiscent of what was observed in the C2C12 Smn-
knockdown cells. Furthermore, skeletal muscle defects such
as vacuolization and compromised sarcomere structures were
reported in human SMA muscle cells co-cultured with rat spinal
cord explants (Braun et al., 1995). Although these primary cell
culture studies were fairly concise, they nonetheless provide valu-
able insight into intrinsic muscle abnormalities. Collectively, the
cell culture and conditional mouse studies were the first to show
muscle intrinsic defects in SMA, and establish and validate a
strong rationale to study muscle defects in the context of SMA.
ABNORMAL SKELETAL MUSCLE DEVELOPMENT IN SMAMICE
A growing body of evidence suggests that Smn-depletion leads
to aberrant skeletal muscle development in SMA model mice. In
the Smn−/−;SMN2;7 mouse model, Lee et al. (2011) showed
that the cross-sectional area of myofibers did not increase from
P5 to P13 suggesting impaired muscle growth. Similarly, the tib-
ialis anterior muscle from phenotype stage Smn−/−;SMN2 mice
show similar cross-sectional area as that in pre-symptomatic
mice (Dachs et al., 2011). A study on patient samples confirms
that SMA muscles demonstrate impaired growth and maturation
characterized by smaller and disorganized myotubes (Martinez-
Hernandez et al., 2009). Collectively, these studies point to defects
in muscle growth, however, the molecular basis for this is still
unclear. One possibility for the reduced myofiber size in mus-
cles from SMA model mice is that it is due to a defect in
post-natal muscle development. Delayed muscle development is
supported by the increased expression of immature myosin heavy
chain (MHC) isoform in SMA model mice. Sustained expres-
sion of the embryonic and perinatal MHC isoforms has been
detected at the transcript and protein level in phenotype stage
Smn−/−;SMN2;7 mice (Kong et al., 2009; Lee et al., 2011).
Furthermore, reduced expression of fast MHC isoforms has been
reported in skeletal muscles of SMA model mice (Biondi et al.,
2008; Lee et al., 2011). The transition between developmental
MHC isoforms and fast MHC isoforms occurs later in develop-
ment compared to slow MHC isoforms (Schiaffino and Reggiani,
2011), therefore delayed muscle development could account for
the decreased expression of type 2B and 2× fibers in SMA mus-
cles. The aberrant MHC expression profile was also associated
with a delay in postsynaptic endplate development. The expres-
sion of the immature acetylcholine receptor persists in severe
SMA model mice and is accompanied by impaired postsynap-
tic maturation at the morphological level (Kariya et al., 2008;
Kong et al., 2009; Dachs et al., 2011; Bowerman et al., 2012a).
A recent study assessed the functional capacities of skeletal mus-
cle and demonstrated muscle weakness was an early feature of
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pathology in multiple mouse models of SMA (Boyer et al., 2013).
Moreover, the severemuscle weakness was associated with delayed
expression of mature isoforms of muscle function proteins such
as ryanodine receptors and sodium channels. For the moment,
direct evidence demonstrating that muscle weakness in SMA
model mice is due to the delayedmyogenesis and aberrant expres-
sion of muscle function proteins is lacking. Nonetheless, together
these results suggest a role for Smn in skeletal muscle develop-
ment. Further, it suggests that low levels of Smn lead to impaired
muscle maturation, and thereby causing muscle weakness.
Hayhurst et al. (2012) have provided evidence suggesting that
Smn-depletion leads to accelerated muscle differentiation in vivo.
Satellite cells, identified by the paired-box transcription factor
Pax7, were increased in number and expressed myogenic mark-
ers earlier in Smn−/−;SMN2 mice compared to controls. Despite
the accelerated expression of the myogenic regulatory factors
in Smn−/−;SMN2 satellite cells, these cells failed to grow upon
differentiation in culture (Hayhurst et al., 2012).
How low levels of Smn lead to specific developmental defects
in SMA model mice is unclear at the moment. However, several
possible scenarios can be envisaged. First, Smn has specific func-
tion(s) during development through its association with one or
more binding partners or second that low levels of Smn disrupts a
major cellular process such as splicing which could impact on the
expression of multiple genes important for muscle development
and function. Thirdly, as muscle development is orchestrated by
activity, defects at the levels of the motor neuron may nega-
tively impact upon the expression of factors controlling post-natal
muscle maturation.
TARGETING PATHWAYS OF MUSCLE ATROPHY IN SMA
Although several attempts have been made to promote muscle
growth in SMA model mice, few studies have begun address-
ing the underlying mechanisms leading to muscle atrophy in the
disease. During skeletal muscle atrophy caused by denervation,
myogenin is up-regulated and directly stimulates the expres-
sion of muscle-specific ubiquitin E3 ligases, namely atrogin 1
and muscle RING-finger protein 1 (MuRF1), collectively referred
to as atrogenes (Moresi et al., 2010). Substrates for atrogin 1
include MyoD, and eIF3f, which is an activator of protein syn-
thesis, while sarcomeric proteins such as myosins and troponins
are substrates of MuRF1 (Bonaldo and Sandri, 2013). Deletion
of either atrogin 1 or MuRF1 leads to complete protection from
denervation-induced muscle atrophy (Bodine et al., 2001).
Recently, a study by Bricceno et al. (2012b) demonstrated
that following phenotype onset, a robust increase in atrogene
expression was observed in SMAmodel mice (Table 1). Increased
myogenin expression correlated with the up-regulation of the
atrogenes, suggesting that the atrophy was mediated by mus-
cle denervation. The expression of myogenin and atrogenes was
also increased in skeletal muscle samples from human patients.
Administration of the histone deacetylase inhibitor trichostatin A
(TSA) prior to muscle atrophy onset attenuated atrogene expres-
sion in amousemodel of SMA (Bricceno et al., 2012b). TSA treat-
ment decreased atrogene expression in denervated mice in which
atrophy is mediated by myogenin but had no effect in a starved
model of atrophy. Thus, this result suggests that TSA directly
impacts on the myogenin dependent atrogene pathway. Direct
Table 1 | Summary of pathways leading to muscle atrophy in motor
neuron diseases.
Molecular pathways leading to atrophy
SMA - increased expression of myogenin, MuRF1 and atrogin 1 in
SMA model mice and SMA human muscle samples
(Bricceno et al., 2012b)
- TSA administration reduced the levels of atrogenes in SMA
model mice (Bricceno et al., 2012b)
ALS - increased levels of atrogin 1 but not MuRF1 in ALS
SOD1G93A model mice and ALS human samples (Léger
et al., 2006)
- decreased levels of AKT in ALS human samples (Léger
et al., 2006)
- increased levels of FoxO3 and MuRF1 but not atrogin1 in
MLC/SOD1G93A animals (Dobrowolny et al., 2005)
- increased levels of expression of autophagy genes in
MLC/SOD1G93A mice (Dobrowolny et al., 2005)
evidence supporting denervation of the muscles used in the study
by Bricceno et al. (2012b) was not presented. Therefore, it is not
fully understood whether the up-regulation of myogenin in SMA
model mice is attributable to impaired myogenesis, muscle dener-
vation or both. Currently, understanding mechanisms of atrophy
in SMA is an understudied area of research. For instance, whether
the autophagic pathway or calpain-mediated muscle breakdown
contribute tomuscle atrophy in SMA is not known but could be of
therapeutic importance. Further dissection of themolecular path-
ways responsible for the muscle atrophy, and testing therapeutics
to treat atrophy in SMA is definitely warranted.
A ROLE FOR SMN IN MUSCLE
By isolating single myofibrils frommyofibers, Walker et al. (2008)
were able to identify Smn as a sarcomeric protein in striated mus-
cle from mice. Specifically, Smn localizes to the Z-disc where it
interacts with the actin crosslinking protein α-actinin (Rajendra
et al., 2007; Walker et al., 2008; Shafey et al., 2010). Interestingly,
other members of the SMN complex such as Gemins 2, 3, 4, and
6 are also present at Z-discs. However, other proteins essential for
snRNP assembly are absent, suggesting that Smn plays a novel role
at this adhesion site.
Currently, it is unclear whether there are any overt cytoskeletal
structural defects inmuscles from SMAmodel mice. Sincemature
muscles require less Smn expression than developing muscle (La
Bella et al., 1998), the residual full-length protein produced by
SMN2 may be sufficient to fulfill its role at the Z-disc. However,
given the localization of Smn in skeletal muscle, the complete
absence of full-length Smn protein in skeletal muscle may lead
to cytoskeletal defects reminiscent of what was observed in Smn
muscle-specific depleted mice. Given the domains present in the
Smn protein, it is unlikely that Smn plays a structural role in
mature myofibers. However, a role for Smn in mechanosensing
may be possible.
INCREASED CELL DEATH IN SMAMUSCLE
To gain insight into intrinsic molecular changes in skeletal mus-
cle prior to motor neuron degeneration, Mutsaers et al. (2011)
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performed a proteomic screen using the rostral band of the
levator auris longus muscle in pre-symptomatic severe SMA
model mice. Several proteins involved in cell death pathways were
aberrantly expressed, some of which were validated in skeletal
muscle from human patients. Furthermore, the authors high-
lighted changes in protein expression that were not identified in
muscle samples from denervated mice, suggesting these changes
are unlikely to be due to defective muscle innervation. In a
separate study, increased apoptotic cell death was observed in
muscles from phenotype stage Smn−/−;SMN2 mice but was not
detected at the pre-symptomatic P0-P1 time point. To demon-
strate that the presence of apoptotic cell death was a muscle
intrinsic phenomenon, Dachs et al. (2011) performed sciatic
nerve denervation in neonatal mice. Forty-eight hours post-
denervation, no increase in apoptotic cells was observed in the
experimentally denervated muscles compared to sham controls.
Therefore, the increased cell death correlates with disease pro-
gression in Smn−/−;SMN2 mice and is not attributed to acute
muscle denervation per se. That said, an investigation of cell death
in Smn-depleted C2C12 cells and cultured satellite cells isolated
from Smn−/−;SMN2 mice revealed normal proportion of apop-
totic cells (Shafey et al., 2005; Hayhurst et al., 2012). Furthermore,
the number of apoptotic cells in type 1 human SMA muscle
samples was comparable to controls (Martinez-Hernandez et al.,
2009). Therefore, it would appear that increased cell death in
skeletal muscle might be limited to mouse models of SMA. How
the absence of Smn leads to increased apoptosis and whether
apoptosis in skeletal muscle is primary or secondary to the SMA
pathogenesis is unclear and requires further study.
THE THERAPEUTIC REQUIREMENTS OF SMN IN SKELETAL MUSCLE
Several therapeutic approaches currently being developed for
the treatment of SMA involve increasing SMN levels. In an
attempt to demonstrate the therapeutic requirements of SMN
in neuronal and muscle tissue, a series of genetic rescues in
mouse models were performed. In an initial study, the expres-
sion of Smn was driven by either the muscle-specific promoter
HSA or by the neuron-specific prion protein promoter (PrP)
(Gavrilina et al., 2008). Crossing HSA and PrP rescue mice onto
the Smn−/−;SMN2 background allowed for a direct comparison
between both the neuronal and muscle approaches on survival.
The longest surviving PrP rescued line lived an average of 210
days while the best surviving HSA rescued line lived an aver-
age of 160 days. Thus, these results demonstrate that rescue in
either neurons or muscle can offer significant improvements in
survival. However, the results from this study are challenging to
interpret given that both the longest surviving muscle and neu-
ronal rescue lines demonstrated leaky Smn protein expression in
the spinal cord and in muscle, respectively. Moreover, the use of
the HSA promoter to express Smn in skeletal muscle may not be
early enough in development, and may therefore not be represen-
tative of when Smn is needed in skeletal muscle. In addition, the
use of the PrP promoter makes it difficult to conclude that Smn
is required precisely in the spinal cord since this promoter targets
multiple cell types in the nervous system.
More recently, a similar study was performed using conditional
SMA model mice expressing tissue-specific Cre drivers, includ-
ing the motor neuron-specific choline acetyltransferase promoter
(ChATcre), and the muscle-specific myogenic determination 1
(MyoDcre) and myogenic factor 5 (Myf5cre). MyoD and Myf5 are
myogenic regulatory factors expressed very early during myoge-
nesis and it was therefore anticipated that they would yield more
significant improvements in the survival of SMA mice (Martinez
et al., 2012). Interestingly, restoring Smn expression in motor
neurons of ChATcre mice led to a very modest increase in sur-
vival (from 15 to 23 days) compared to the survival reported using
the PrP promoter. The ChATcre extended survival 2 days more
than the muscle-specific promotersMyoDcre andMyf5cre. ChATcre
conditional mice showed increased SMN expression in motor
neurons and improved neuromuscular junction function and
morphology. Despite these improvements, only the MyoDcre and
theMyf5cre lines produced a robust increase in the cross-sectional
area of myofibers. It should be noted that Smn expression from
the Myf5cre driver was detectable in the neuronal tissue making
it somewhat difficult to interpret the results from this particular
conditional mouse model (Martinez et al., 2012). Nonetheless,
the results from MyoDcre and Myf5cre demonstrate the impor-
tance of restoring Smn expression in skeletal muscle and suggest
that a combinatorial expression of Smn in both myofibers and
motor neurons may provide a more impressive extension of life
in mouse models of SMA. These data, suggest that restoration of
Smn expression in skeletal muscle should not be overlooked when
developing therapeutic strategies.
INDUCING MUSCLE GROWTH PATHWAYS IN SMAMODEL MICE
In an effort to reverse the muscle atrophy phenotype in mouse
models of SMA, researchers have attempted to stimulate mus-
cle growth pathways by various means. Myostatin is a potent
negative regulator of muscle mass and the modulation of the
myostatin pathway leads to dramatic muscle growth (Lee and
McPherron, 2001). It was therefore hypothesized that modulation
of the myostatin pathway may lead to phenotypic improvements
in mouse models of SMA. Interestingly, myostatin and follis-
tatin, a myostatin antagonist, were both found to be increased
in mouse models of SMA suggesting a possible compensatory
attempt by the animal to minimize muscle size loss (Sumner et al.,
2009). Genetic overexpression of myostatin in SMA model mice
proved to have a modest effect on muscle weight but offered
no improvements in motor function and survival (Rindt et al.,
2012). In a similar study, the genetic overexpression of follistatin
in SMA model mice did not increase myofiber size or improve
lifespan (Sumner et al., 2009). However, administration of recom-
binant follistatin in the same SMA mouse models used as in the
genetic overexpression studies had a positive effect on the disease
phenotype and lifespan (Rose et al., 2009). Specifically, deliv-
ery of the recombinant follistatin increased muscle mass, body
weight, improved motor function and also increased motor neu-
ron numbers and size in SMA model mice. Collectively, these
changes led to an increase in median survival time. The differ-
ences in results between both follistatin studies are unclear but
are likely attributed to the different methods used to overexpress
follistatin that is, genetic overexpression versus administration of
recombinant protein.
Insulin-like growth factor 1 (IGF-1) is a robust positive reg-
ulator of muscle mass and the overexpression of IGF-1 in mice
causes a dramatic increase in musculature (Musaro et al., 2001).
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Interestingly, circulating IGF-1 levels are reduced in multiple
mouse models of SMA (Hua et al., 2011; Murdocca et al., 2012).
Delivery of IGF-1 to the central nervous system of type III SMA
model mice using an adeno-associated virus vector proved ben-
eficial for motor neuron health but had little effect on myofiber
integrity and motor function (Tsai et al., 2012). The systemic
administration of IPLEX (recombinant human IGF-1 complexed
with recombinant human IGF-1 binding protein 3) by intraperi-
toneal injection in Smn−/−;SMN2;7 animals led to increased
myofiber size, reduced motor neuron cell loss but did not impact
on life span and body weight of SMA model mice (Murdocca
et al., 2012). Finally, combining SMN trans-splicing with an IGF-
1 vector increased life span and body mass in a severe mouse
model of SMA (Shababi et al., 2011). It is difficult to partial out
whether the improvements in myofiber size were due to the IGF-
1 protein acting on myofibers directly or rather, increased muscle
size was a secondary consequence from the healthier motor neu-
rons. The genetic muscle overexpression of IGF-1 onto the same
SMA background used in the follistatin studies led to increased
muscle mass as well as an increase in the median lifespan (Bosch-
Marce et al., 2011). Overexpression of muscle IGF-1 had little
effect on markers of muscle maturity. Therefore, IGF-1 cannot
restore proper muscle development in SMA model mice. IGF-1
may prove to be of greater benefit to diseases in which myofibers
have formed and matured properly and are subsequently affected
by intrinsic and extrinsic pathology. In fact, promoting muscle
growth using IGF-1 overexpression before the muscle has fully
matured may be detrimental to the tissue. Furthermore, it should
be noted that the SMAmodel mice were crossed to IGF-1 overex-
pressing heterozygotes. Therefore, the benefits of IGF-1 may have
been more obvious had the mice been bred to homozygosity.
Perhaps targeting molecules more downstream where myo-
statin and IGF-1 pathways converge might yield more robust
results. For example, Akt is downstream of both myostatin and
IGF-1, and overexpression of Akt in mice has led to increased
muscle size (Lai et al., 2004; Schiaffino and Mammucari, 2011).
In addition to promoting muscle growth, Akt also plays an
important role in inhibiting mechanisms of atrophy including
inhibiting atrogenes and the autophagic pathway (Schiaffino and
Mammucari, 2011).
AMYOTROPHIC LATERAL SCLEROSIS (ALS)
DISEASE CHARACTERISTICS
ALS is a progressive adult-onset fatal disease characterized by the
selective degeneration of upper motor neurons in the cerebral
cortex and lower motor neurons of the brain stem and spinal cord
(Rowland and Shneider, 2001). Features of the disease include
muscle weakness and atrophy, spasticity and paralysis. It has an
incidence of two per 100,000 people per year in the United States
(Rowland and Shneider, 2001).
The term “amyotrophic” refers to the muscle atrophy, weak-
ness and fasciculation that signify disease of lower motor neu-
rons, while “lateral sclerosis” refers to the hardening of lateral
columns, where gliosis follows the degeneration of corticospinal
tracts (Rowland and Shneider, 2001). The mean duration of sur-
vival for ALS patients is 3–5 years following disease onset, with
denervation of the respiratory muscles and diaphragm generally
representing the fatal event of the disease. Despite intense research
efforts, limited therapeutic options remain in attenuating disease
progression; nevertheless advances are being made in palliative
therapy (Carter et al., 2012).
A vast majority of ALS cases are sporadic and have no known
genetic component, except for missense mutations in the TAR-
DNA binding protein (Kabashi et al., 2008). Inherited forms of
ALS (fALS) have an autosomal dominant or recessive pattern of
inheritance and constitute ∼10% or less of the remaining ALS
cases (Rowland and Shneider, 2001). In 1993, a breakthrough in
ALS research was made with the discovery of missense mutations
in the Cu/Zn superoxide dismutase 1 (SOD1) gene of a subset
of fALS cases (Rosen et al., 1993). It is estimated that 15–20%
of fALS patients harbor missense mutations in the SOD1 gene
(equating to 2% of all ALS cases).
SOD1 is a ubiquitously expressed cytosolic metalloprotease
that non-covalently binds Cu and Zn. The enzyme functions
by detoxifying and maintaining intracellular superoxide anions
(O2−) by catalyzing the dismutation of O2− to molecular oxy-
gen and hydrogen peroxide. As such, mutations in SOD1 impart
oxidative stress, which has become a key mechanism underly-
ing disease pathogenesis (Barber et al., 2006). That said, to date,
a number of different pathogenic mechanisms are believed to
trigger ALS pathogenesis (Ilieva et al., 2009).
Most of our current knowledge of ALS pathogenic mecha-
nisms comes from transgenic mice expressing various forms of
mutant SOD1. Studies with these mice have highlighted multiple
targets of damage in disease including mitochondria, protea-
somes, and secretory pathways. Furthermore, while expression of
mutant SOD1 within motor neurons is a primary determinant
of disease onset and of an early phase of disease progression, the
expression of mutant SOD1 also affects structural, physiological,
andmetabolic parameters in other cell types (e.g., glia and skeletal
muscle) (see reviews Boillee et al., 2006; Ilieva et al., 2009). ALS is
now considered a multisystemic disease, wherein a variety of cell
types act synergistically to exacerbate disease pathogenesis (Ilieva
et al., 2009).
The progressive paralysis in ALS is the result of degener-
ation and demise of motor neurons (Rowland and Shneider,
2001). Data frommultiple studies suggest that toxicity is non-cell-
autonomous, meaning toxicity to motor neurons derives from
damage developed within cell types beyond the motor neuron
(see reviews Fuchs et al., 1994; Boillee et al., 2006; Ilieva et al.,
2009). Studies supporting this notion showed that ubiquitous
transgenic overexpression of SOD1 mutations causing fALS leads
to an ALS phenotype in mice (Wong et al., 1995), however,
restricted expression of mutant SOD1 in neurons alone is not
sufficient to cause this phenotype. It is perhaps important to
note, however, that levels of mutant SOD1 selectively expressed
in motor neurons may have been too low to initiate disease
(Pramatarova et al., 2001; Lino et al., 2002). More recent studies
suggest that neuron-specific expression of human mutant SOD1
in mice triggers motor neuron degeneration (Jaarsma et al., 2008;
Wang et al., 2008). These discrepant studies indicate that mutant
SOD1-induced motor neuron degeneration is at least partly cell
autonomous, and non-neuronal mutant SOD1 expression is also
likely required for disease manifestation.
www.frontiersin.org December 2013 | Volume 4 | Article 356 | 5
Boyer et al. Intrinsic muscle defects in MNDs
MUSCLE DEFECTS IN ALS
Numerous studies support the notion that multiple tissues out-
side the CNS, including skeletal muscle (Wiedemann et al., 1998;
Krasnianski et al., 2005; Dupuis et al., 2006), fibroblasts (Aguirre
et al., 1998;McEachern et al., 2000), and lymphocytes (Cova et al.,
2006) are affected in human ALS. In both sporadic and fALS,
functional aberrations and skeletal muscle pathology are present
including neurogenic-induced muscle pathology and mitochon-
dria dysfunction (Vielhaber et al., 1999; Krasnianski et al., 2005;
Echaniz-Laguna et al., 2006; Corti et al., 2009). Similarly, trans-
genic mice expressing mutant SOD1 recapitulate functional and
metabolic deficits in skeletal muscle as seen in human ALS
patients (Derave et al., 2003; Dupuis et al., 2004; Mahoney et al.,
2006).
Selective expression of mutant SOD1 in mouse skeletal muscle
using the myosin light chain (MLC) promoter (MCL/SOD1G93A)
induced ALS-like muscle pathologies, including progressive
muscle atrophy, reduced muscle strength, impaired contractil-
ity, and mitochondrial dysfunction (Dobrowolny et al., 2008).
Interestingly, exclusive expression of mutant SOD1 in skeletal
muscle did not trigger the degeneration of motor neurons. This
finding contrasts with a similar study from Wong and Martin
(2010), where human mutated SOD1 expression driven from the
HSA promoter, resulted in pathologic phenotypes in both mus-
cle and motor neurons reminiscent of ALS (Wong and Martin,
2010). The reasons for this discrepancy is unclear although it may
be due to the fact the animals used were of a different age, being
significantly younger in the work from Dobrowolny et al. (2008).
Regardless of this, together these studies provide strong evidence
that mutant SOD1 is toxic to skeletal muscle and challenged the
accepted dogma that motor neuron degeneration, caused by the
overexpression of mutant SOD1, is the principle driver of muscle
atrophy.
Skeletal muscle mitochondrial defects have been reported in
MLC/SOD1G93A mice as well as in other mouse models of ALS
(Dupuis et al., 2003, 2004; Dobrowolny et al., 2008). Previous
studies have suggested that mitochondrial defects may lead to
motor neuron degeneration in the context of ALS. This notion
is supported by the study of Dupuis et al. (2009) in which they
demonstrate that muscle mitochondria uncoupling leads to mus-
cle denervation and motor neuron degeneration. Furthermore,
muscle mitochondria uncoupling exacerbates disease progression
and survival in a mouse model of ALS (Dupuis et al., 2009).
MYOGENESIS IN ALS
Altered expression of the myogenic program has previously been
reported in a mouse model of ALS. Widespread differences in
the transcript and protein levels of Pax7 and myogenic regula-
tory factors were reported at disease onset (Manzano et al., 2011).
The up-regulation of these proteins may reflect an increase in
satellite cell activation following myofiber degeneration that may
occur at time of disease onset. The levels of myogenic regulatory
factors were not differentially expressed in early and late pre-
symptomatic ALS mice compared to controls. This result suggests
that the aberrant expression of the myogenic program is unlikely
to be a triggering event leading to skeletal muscle defects in ALS
model mice. In a separate study, however, primary myoblasts
isolated from ALS patients and induced to differentiate into
myotubes showed decreased expression of MHC, and displayed
fusion defects (Pradat et al., 2011). These results are reminis-
cent of what was observed in SMA and SBMA cell culture studies
(Arnold et al., 2004; Shafey et al., 2005; Malena et al., 2013).
MECHANISMS OF ATROPHY IN ALS
The most overt symptom in ALS patients is muscle weakness,
which ultimately leads to death. Understanding mechanisms of
muscle atrophy in ALS, i.e., whether muscle atrophy in ALS is
solely due to denervation or whether it is intrinsic, may offer
potential therapeutic avenues able to alleviate atrophy-induced
weakness. Léger et al. (2006) studied signaling pathways con-
tributing to skeletal muscle atrophy using ALS human samples as
well as ALS SOD1G93A model mice. A dramatic increase in the
expression of the E3 ubiquitin ligase atrogin 1 was detected in
both mouse and human ALS samples. No changes were observed
in the expression ofMuRF1 (Table 1) (Léger et al., 2006). Changes
upstream of atrogenes have also been reported. IGF-1 levels were
decreased and the expression of activated Akt was down-regulated
suggesting that muscle atrophy was associated in part to intrin-
sic defects not associated with myogenin-induced atrophy during
denervation (Léger et al., 2006; Lunetta et al., 2012). Further evi-
dence demonstrating that muscle atrophy is not entirely neuro-
genic in nature comes from studies with MLC/SOD1G93A mouse
models of ALS in which restricted mutated SOD1 expression
to skeletal muscle leads to atrophy (Dobrowolny et al., 2008).
Skeletal muscle atrophy in these mice is initiated by the Akt
pathway which suppresses protein synthesis and induces FoxO3
mediated expression of atrogenes (e.g., atrogin1 and MuRF1)
(Dobrowolny et al., 2011). Furthermore, transcript levels of genes
in the autophagic pathway such as LC3, Bnip3, and CathepsinL
(Table 1) are up-regulated in muscles from MLC/SOD1G93A ani-
mals and may contribute to decreased myofiber size while cas-
pases are likely end stage contributors to atrophy in these mice
(Dobrowolny et al., 2008, 2011). These pathways altered in
ALS conditional mice differ from the myogenin-induced atro-
phy observed following denervation. This supports the idea
that intrinsic atrophy mechanisms are contributing to decreased
myofiber size in ALS and that therapeutic approaches to reverse
atrophy and increase myofiber size may prove beneficial in this
disease. Based on these studies, it is difficult to overlook the
importance of skeletal muscle as a contributor to the pathogenesis
of ALS.
SKELETAL MUSCLE IGF-1 AS A THERAPEUTIC APPROACH IN ALS
The muscle-specific overexpression of IGF-1 has led to remark-
able improvement in ALS model mice. Using the muscle MLC
promoter, Dobrowolny et al. (2005) overexpressed IGF-1 onto
the SOD1G93A mouse model of ALS (SOD1G93A/mIgf-1). This
delayed disease onset and increased survival. Muscle atrophy
was attenuated and satelitte cell activation was enhanced in
SOD1G93A/mIgf-1 mice (Dobrowolny et al., 2005). Importantly,
IGF-1 overexpression in muscle also preserved neuromuscular
junction integrity and protected motor neurons from degenera-
tion.
It has also been reported that viral delivery of IGF-1 to skeletal
muscles leads to increased survival and protected motor neurons
in ALS model mice (Kaspar et al., 2003). Interestingly, muscle
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viral delivery of IGF-1 in ALSmodel mice combined with exercise
has a remarkable synergistic effect leading to an increase in sur-
vival beyond what was obseved following gene therarpy or exer-
cise alone (Kaspar et al., 2005). It remains to been seen whether
the adminstration of IGF-1 gene therapy combined with treat-
ment of exercise mimetics such as AICAR and GW501516, can
yeild similar results since exercise is likely not a feasable longterm
option in severe ALS patients. Despite significant improvements
in ALS model mice achieved by genetic or viral overexpression of
IGF-1, to date efficacy studies of recombiant IGF-1 have yeilded
positvie results in two human trials while a third trial reported no
improvements in muscle strength. However, no trial has demon-
stated any imporovments regarding patient survival (Beauverd
et al., 2012).
SPINAL AND BULBAR MUSCULAR ATROPHY (SBMA)
DISEASE CHARACTERISTICS
Spinal and bulbar muscular atrophy (SBMA), also known as
Kennedy’s disease, is an adult onset neuromuscular disease char-
acterized by the degeneration and loss of lower motor neurons
leading tomuscle wasting. The initial phase of the disease presents
as muscle cramping, hand tremors and fatigue, withmuscle weak-
ness considered a late manifestation of disease (Sambataro and
Pennuto, 2012). In addition to muscle weakness, SBMA patients
display other symptoms such as fasciculations that are especially
prevalent in the face, neck and tongue. The disease affects an
estimated 1–2 per 100,000 people (Katsuno et al., 2012).
At the molecular level, SBMA is caused by the expansion of
a polyglutamine (polyQ)-encoding CAG trinucleotide repeat in
the first exon of the gene coding for the androgen receptor (AR).
These repeats are toxic and lead to motor neuron death causing
respiratory weakness in SBMA patients (Bricceno et al., 2012a).
Motor neurons express high levels of the AR relative to other neu-
ronal populations, and the loss of AR function attributed to the
expanded polyQ tract is believed to contribute to SBMA patho-
genesis. However, the predominant disease mechanism involves
a gain-of-toxic function that accompanies the expanded polyQ
tract AR in motor neurons (Katsuno et al., 2012).
A correlation exists between the number of repeats and the
age at onset of muscle weakness (Igarashi et al., 1992). Full dis-
ease manifestations are observed in men only while heterozygous
females are mostly asymptomatic and women homozygous for
the mutation are rare and show only mild symptoms (Schmidt
et al., 2002). The AR gene is located on the proximal arm of chro-
mosome Xq11-12 (Katsuno et al., 2012). The AR is a nuclear
receptor and is part of the steroid/thyroid hormone receptor
family. Upon binding to its natural ligands testosterone and dihy-
drotestosterone, the AR is translocated to the nucleus where
it binds DNA as well as transcriptional co-regulators to con-
trol the expression of a subset of genes. However, pathological
CAG triplet repeats in the AR lead to the nuclear accumula-
tion of the receptor and this disrupts its transactivation domain’s
ability to interact with transcriptional co-activators. The AR is
required for androgen dependent changes including proper male
pubertal sexual development. SBMA patients demonstrate subtle
androgen sensitivity highlighted by gynecomastia, fertility com-
plications and atrophy of the gonads (Sambataro and Pennuto,
2012). Castration of SBMA model mice prevents any phenotype
while treating female animals with testosterone exacerbates the
phenotype (Katsuno et al., 2002). These results demonstrate that
disease manifestations are androgen-dependent and this explains
the gender bias observed in SBMA patients.
MUSCLE DEFECTS IN SBMA PATIENTS
Although SBMA is believed to be primarily a motor neuron
disease, increasing evidence suggests that myogenic defects con-
tribute significantly to the disease pathogenesis. Studies per-
formed on SBMA patients report very high levels of serum
creatine kinase (CK), which are often 10 times higher than nor-
mal (Lee et al., 2005). It has been demonstrated that CK levels
are higher in SBMA than any other motor neuron or myopathic
disease and the increase can be detected prior to the onset of
SBMA clinical symptoms (Chahin and Sorenson, 2009). Elevated
serum CK levels are indicative of muscle damage and often seen
in muscular dystrophy patients.
Histological studies performed on SBMA patients’ muscle
biopsies have revealed the presence of both neurogenic and
primary myogenic defects. With muscle samples from SBMA
patients, Sorarù et al. (2008), demonstrate the presence of
fiber type grouping, atrophic fibers and angulated fibers, which
are defects observed following chronic denervation. Necrotic
myofibers as well as myofibers with centrally located nuclei,
which are indicative of regenerating fibers, are also observed in
SBMAmuscle biopsies and are associated with primary myogenic
changes (Sorarù et al., 2008; Chahin and Sorenson, 2009).
Studies using primary myoblasts isolated from SBMA patients
have demonstrated that these cells proliferate and differentiate
normally (Malena et al., 2013). Furthermore, primary SBMA
myoblasts express myogenic regulatory factors such as MyoD
and myogenin at levels comparable to controls. These results are
androgen-dependent and suggest that early myogenesis is not
affected in SBMA. However, defects such as cytoskeletal perturba-
tions as well as aberrantmyotube fusion were observed in primary
myoblasts isolated from SBMA patients.
MUSCLE DEFECTS IN MOUSE MODELS OF SBMA
The use of mouse models has significantly contributed to our
understanding of the myogenic defects in the SBMA phenotype.
Yu et al. (2006) used gene targeting to generate a mouse model
in which they converted the mouse AR sequence to the human
sequence and in the process introduced 113 CAG repeats to
recapitulate the human phenotype. These knock-in mice, desig-
nated AR113Q, are smaller, weaker compared to control coun-
terparts, and die at 2–4 months of age. Histologically, muscles
from AR113Q mice have atrophic and angulated fibers. At the
molecular level, myogenin and acetylcholine receptor expression
were up-regulated in AR113Q mice while MyoD expression was
unchanged compared to controls. These morphological and gene
expression changes are reflective of those observed following den-
ervation (Moresi et al., 2010). Furthermore, myogenin was not
mis-regulated in primary SBMA myoblasts supporting the idea
that myogenin-dependent atrophy is present in AR113Q mice
(Malena et al., 2013). However, the skeletal muscle pathology in
AR113Q animals was thought to be cell-autonomous because it
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was detected prior to overt polyQ tract-induced pathology in the
spinal cord. These results raise the possibility that the AR toxi-
city occurs in muscle prior to motor neurons, and may be the
initiating factor leading to denervation-induced atrophy.
Other histological changes such as myofibers with centrally
located nuclei present in AR113Q mice are more reflective of
intrinsic myopathic defects. The expression of genes important
for muscle function, such as the muscle chloride channel 1
(CLCN-1) and the muscle-specific sodium channel SCN4A, were
decreased in AR113Q animals. The levels of CLCN-1 and SCN4A
have previously been shown to decrease following experimental
denervation (Kallen et al., 1993; Klocke et al., 1994). However,
subsequent analyses in AR113Q animals demonstrated that the
mis-regulation of CLCN-1 and SCN4A was not due to dener-
vation (Yu et al., 2006). Furthermore, the down-regulation of
CLCN-1 is attributed to the mis-splicing of the gene, which is
reminiscent of what is observed in the muscle disease myotonic
dystrophy (Yu et al., 2009). Therefore, SBMA model mice show
muscle defects that are both intrinsic and motor neuron depen-
dent. The denervation-like defects in AR113Q skeletal muscles
can either be associated with intrinsic muscle toxicity-induced
denervation, or to a secondary consequence linked tomuscle den-
ervation since the innervation status of skeletal muscles was not
directly assessed.
Perhaps more compelling evidence supporting muscle contri-
butions to SBMA pathogenesis comes from a mouse model in
which a wild type AR was overexpressed in skeletal muscle and
recapitulated the phenotypic features observed in other mouse
models of SBMA (Monks et al., 2007). In this model, the AR
overexpression in skeletal muscle was achieved using the HSA
promoter (AR-HSA). AR-HSA animals showed muscle pathol-
ogy and molecular changes such as increased levels of myogenin
and AChR that are reminiscent of those observed following den-
ervation. Interestingly, AR-HSA transgenic mice did not display
motor neuron cell body loss but rather exhibited axonopathy.
Again, these data suggest that the AR muscle toxicity may lead to
motor neuron axon loss that in turn leads to denervation-induced
pathology in skeletal muscles. Moreover, this result indicates that
motor neuron defects occur distally first and eventually lead
to cell body loss, a dying back phenomena, and may therefore
explain the phenotype observed in the AR113Q mouse model
of SBMA. The authors demonstrate that the toxicity to muscle
occurred upon the activation of the AR-HSA by its ligand rather
than the overexpression of the AR-HSA per se. However, it is dif-
ficult to conclude that the results observed from the AR-HSA
mousemodel can be directly generalized to SBMA, especially con-
sidering that the molecular pathogenesis of the AR-HSA model,
which lacks the expanded polyQ tract, is very different.
SKELETAL MUSCLE AS A THERAPEUTIC TARGET IN SBMA
It has long been known that AR translocation to the nucleus is
ligand-mediated and that this process is intensified in men given
that the AR ligand is testosterone. Modifying testosterone levels
in SBMAmodel mice is a ligand-targeted therapy that has proven
very successful. In a mouse model of SBMA in which 97 CAG
repeats were introduced into the AR gene (AR97Q), reduction of
testosterone by way of castration prevented the appearance of the
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phenotype in male mice (Katsuno et al., 2002). In AR97Q female
animals, administration of testosterone induced aberrant motor
phenotypes and neuropathology. Treatment of AR-HSA female
mice with testosterone provoked denervation-like symptoms sim-
ilar to AR-HSA males. However, upon testosterone treatment
cessation, AR-HSA females recovered normal motor function and
expressed muscle genes at usual levels (Johansen et al., 2009). In
agreement with these findings, survival and muscle pathology of
AR-HSA mice is significantly ameliorated by prenatal treatment
with flutamide, an AR antagonist. These data reveal that the AR
expression restricted tomuscle alone can lead to SBMA symptoms
inmice and that these defects can be improved by blocking andro-
gen binding. Thus, the SBMA phenotype strongly correlates with
androgen expression and skeletal muscle may be an important
target for SBMA treatment.
Although the use of anti-androgens is effective in treating
mouse models of SBMA, it may prove to have unwanted side
effects in humans. In an attempt to better understand how the
AR is endogenously regulated, Palazzolo et al. (2007) uncov-
ered a role for Akt in regulating AR function. Phosphorylation
of the AR by Akt represses the AR activity through a ligand-
dependent manner, thus preventing androgen from activating the
AR. Modulation of Akt in cell culture models of SBMA rescued
the polyQ associated cell toxicity indicating that manipulating
the Akt pathway might provide phenotypic improvements in
SBMA model mice (Palazzolo et al., 2007). Indeed, skeletal mus-
cle overexpression of IGF-1, a protein that acts upstream of Akt,
delayed disease onset and extended survival in SBMAmodel mice
(Palazzolo et al., 2009). IGF-1 activates Akt and thus increases AR
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phosphorylation, which in turn reduces AR nuclear accumulation
in muscles from SBMA model mice. A striking observation was
that overexpression of IGF-1 in skeletal muscle improved motor
behavior and reduced motor neuron cell loss in SBMA model
mice. IGF-1 overexpression in skeletal muscle ameliorated both
myofiber andmotor neuron health by reducing AR nuclear aggre-
gates. IGF-1 has previously been shown to benefit motor neurons
by promoting sprouting and axonal growth, therefore IGF-1 may
improve motor neuron health via its trophic properties in addi-
tion to its effects on mutant AR (Caroni and Grandes, 1990).
Furthermore, overexpression of IGF-1 in skeletal muscle of wild
type mice leads to gross muscle hypertrophy (Musaro et al.,
2001). Therefore, IGF-1might ameliorate muscle pathology inde-
pendently of AR even though gene array data suggest that the
IGF-1 signaling pathway is largely unaffected in skeletal muscle
of multiple mouse models of SBMA (Mo et al., 2010).
Taken together, muscle defects are evident in SBMA and for
the most part, were believed to be a secondary response to mus-
cle denervation. However, a growing body of evidence supports
the notion that muscle is the primary target of polyQ-AR toxic-
ity and that muscle defects lead to motor neuron abnormalities.
Results from various mouse models and muscle-specific targeted
therapies support this idea.
CONCLUSION
Although considered motor neuron diseases, the use of condi-
tional mouse models as well cell culture systems have highlighted
the contributions of intrinsic skeletal muscle defects in SMA,
ALS and SBMA (Table 2). The nature of the skeletal muscle
defects differs between these three diseases. For instance, the
most notable muscle defects in SMA are associated primarily with
impaired development but defects neurogenic in origin are also
observed. While in ALS, muscle defects are due to intrinsic and
neurogenic factors, and appear to be present in mature myofibers
rather than in developing muscle. In SBMA, cell-autonomous
muscle degeneration is an overt contributor to the phenotype as
are denervation-induced defects. However, results from ALS and
SBMA mouse models suggest that in these diseases, skeletal mus-
cle defects can initiate motor neuron defects. Such evidence to
support this notion in SMA is currently lacking, indeed the com-
plete absence of Smn in skeletal muscle was not associated with
motor neuron defects (Cifuentes-Diaz et al., 2001). The use of
appropriate conditional animals models will serve to explore this
possibility further.
A common therapeutic approach used in all three dis-
eases involves the muscle-specific overexpression of IGF-1. This
approach has led to remarkable improvements in mouse models
of ALS and SBMA, and to a lesser degree in SMA. The reason
for this may be associated to the type of muscle defects in these
diseases. The IGF-1 therapeutic approach may prove to be more
beneficial in the context of mature muscle that is diseased, and
may not be as efficient in SMA where muscle development is
impaired.
It has always been assumed that muscle defects in SMA,
ALS, and SBMA were a secondary consequence of motor neu-
ron pathology. However, the studies described in this review shed
light onto the importance of intrinsic muscle defects as a primary
contributor to the pathogenesis of these diseases. As such, more
research should be focused on treating intrinsic skeletal mus-
cle defects. Indeed, regardless of whether muscle is a primary or
secondary contributor to the pathogenesis of these diseases, mus-
cle defects are present and therefore muscle is still an important
therapeutic target to consider.
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